|
1
|
Wolf J, Seto T, Han JY, Reguart N, Garon
EB, Groen HJ, Tan DSW, Hida T, de Jonge M, Orlov SV, et al:
Capmatinib (INC280) in patients (pts) with METex14-mutated advances
NSCLC: An update from phase 2 GEOMETRY mono-1 study. Pneumologie.
74((S 01)): S1342020.
|
|
2
|
Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan
C, Wu Y, Li X, Li X, Li G, et al: Function of the c-Met receptor
tyrosine kinase in carcinogenesis and associated therapeutic
opportunities. Mol Cancer. 17:452018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu YL, Zhang L, Kim DW, Liu X, Lee DH,
Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, et al: Phase
Ib/II study of capmatinib (INC280) plus gefitinib after failure of
epidermal growth factor receptor (EGFR) inhibitor therapy in
patients with EGFR-mutated, MET factor-dysregulated non-small-cell
lung cancer. J Clin Oncol. 36:3101–3109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kubo K, Azuma A, Kanazawa M, Kameda H,
Kusumoto M, Genma A, Saijo Y, Sakai F, Sugiyama Y, Tatsumi K, et
al: Consensus statement for the diagnosis and treatment of
drug-induced lung injuries. Respir Investig. 51:260–277. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Antoniou KM, Margaritopoulos GA,
Tomassetti S, Bonella F, Costabel U and Poletti V: Interstitial
lung disease. Eur Respir Rev. 23:40–54. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kanemura H, Takeda M, Shimizu S and
Nakagawa K: Interstitial lung disease associated with capmatinib
therapy in a patient with non-small cell lung cancer harboring a
skipping mutation of MET exon 14. Thorac Cancer. 12:549–552. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hashiguchi MH, Sato T, Yamamoto H,
Watanabe R, Kagyo J, Domoto H and Shiomi T: Successful tepotinib
challenge after capmatinib-induced interstitial lung disease in a
patient with lung adenocarcinoma harboring MET exon 14 skipping
mutation: Case report. JTO Clin Res Rep. 3:1002712021.PubMed/NCBI
|
|
8
|
Tseng LW, Chang JWC and Wu CE: Safety of
tepotinib challenge after capmatinib-induced pneumonitis in a
patient with non-small cell lung cancer harboring MET exon 14
skipping mutation: A case report. Int J Mol Sci. 23:118092022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang YP, Lee SB, Lee JM, Kim HM, Hong JY,
Lee WJ, Choi CW, Shin HK, Kim DJ, Koh ES, et al: Metabolic
profiling regarding pathogenesis of idiopathic pulmonary fibrosis.
J Proteome Res. 15:1717–1724. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rindlisbacher B, Schmid C, Geiser T, Bovet
C and Funke-Chambour M: Serum metabolic profiling identified a
distinct metabolic signature in patients with idiopathic pulmonary
fibrosis-a potential biomarker role for LysoPC. Respir Res.
19:72018. View Article : Google Scholar : PubMed/NCBI
|
